# Lead Healthcare.AI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lead-healthcare-ai

- Industry: Medical Devices & Equipment
- Headquarters: Guangzhou, China
- Website: www.leadhealth.com.cn
- Total disclosed funding: $14M
- Latest round: Angel (May 22, 2025)
- Investors on record: 5

## About

Based in Guangdong, China, and founded in 2023, Lead Healthcare.AI (Guangzhou) Co., Ltd., trading as Lead Healthcare.AI, develops automation and intelligent system solutions for life science instruments and biopharmaceutical applications. In September 2026, Lead Healthcare.AI raised a Pre-series A++ funding from Shanghai Shangguo Investment Management.

The company focuses on applied technologies supporting pharmaceutical research, biomanufacturing, and laboratory operations. Its offerings support laboratory operations, bioprocess workflows, and system-level efficiency improvements. The company has established a comprehensive portfolio spanning core technologies, key components, and system-level solutions. It has launched over 20 high-end products—including AI-driven large models for intelligent cell recognition, "AI for Science" automation equipment, high-throughput AI imaging flow cytometers, fully automated stem/immune cell culture and preparation systems, AI-based organoid drug screening systems, single-cell multi-omics systems, and microfluidic system modules.

The company generates revenue by developing, manufacturing, and selling life science instruments, biomanufacturing equipment, and AI-enabled automation solutions for research and biopharmaceutical customers.

The Pre-series A++ funding raised in September 2026 will be primarily allocated to strengthening business operations in East China, recruiting top-tier talent, accelerating the development of high-end scientific instruments and "AI for Science" capabilities, scaling up production capacity, and expanding nationwide market channels.
Moving forward, Lead Healthcare.AI will continue to increase R&D investment in AI algorithms and models, AI data centers, core components, and systematic solutions. The company will deepen the integration of AI with life sciences, medical devices, biopharmaceuticals, biomanufacturing, and high-end scientific instruments; tackle critical "bottleneck" technologies in the high-end instrument sector; and continuously iterate on competitive AI-driven life science instruments and digital-intelligent biomanufacturing platforms.

## Funding rounds

- Angel, May 22, 2025, $14M — Casstar Capital, Jiadaogu Capital, Vipassana Fund, KESHENG, Together To Miracle

## Investors

- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Angel
- Jiadaogu Capital (https://capitalatlas.ai/funds/jiadaogu-capital) — Angel
- Vipassana Fund — Angel
- KESHENG — Angel
- Together To Miracle — Angel